Merck and partner Ridgeback Biotherapeutics said on Friday six lab studies showed that their experimental oral COVID-19 drug, molnupiravir, was active against the Omicron variant.
Merck's COVID-19 pill effective against Omicron in lab studies
By REUTERS
12/25/2024 11:29 AM
By REUTERS
12/25/2024 11:24 AM
By REUTERS
12/25/2024 07:02 AM
By WALLA!
12/25/2024 03:46 AM